Cowen and Company Reaffirms “Outperform” Rating for Allergan PLC. (NYSE:AGN)

Allergan PLC. (NYSE:AGN)‘s stock had its “outperform” rating reaffirmed by research analysts at Cowen and Company in a report issued on Tuesday, August 29th. They presently have a $400.00 price target on the stock. Cowen and Company’s target price would indicate a potential upside of 81.58% from the stock’s current price.

Several other analysts also recently issued reports on the company. BidaskClub downgraded Allergan PLC. from a “sell” rating to a “strong sell” rating in a research note on Friday, August 25th. Cantor Fitzgerald reissued a “hold” rating on shares of Allergan PLC. in a research report on Tuesday, August 22nd. Argus reissued a “buy” rating and set a $280.00 target price on shares of Allergan PLC. in a research report on Monday, August 14th. UBS AG reissued an “outperform” rating and set a $275.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 9th. Finally, Deutsche Bank AG reissued a “buy” rating and set a $278.00 target price (up previously from $273.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the stock. Allergan PLC. has a consensus rating of “Buy” and a consensus target price of $274.69.

Allergan PLC. (NYSE AGN) traded down 1.52% on Tuesday, hitting $220.29. 3,347,884 shares of the stock traded hands. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company has a market cap of $73.64 billion, a price-to-earnings ratio of 6.71 and a beta of 1.18. The stock has a 50-day moving average price of $231.75 and a 200 day moving average price of $236.59.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company earned $3.35 EPS. On average, analysts anticipate that Allergan PLC. will post $16.25 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Cowen and Company Reaffirms “Outperform” Rating for Allergan PLC. (NYSE:AGN)” was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/allergan-plc-agn-earns-outperform-rating-from-cowen-and-company/1565706.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Intl Fcstone Inc. purchased a new stake in shares of Allergan PLC. in the second quarter worth about $1,626,000. Phocas Financial Corp. purchased a new stake in shares of Allergan PLC. in the second quarter worth about $150,000. Sentry Investment Management LLC boosted its position in Allergan PLC. by 1.0% during the second quarter. Sentry Investment Management LLC now owns 26,889 shares of the company’s stock worth $6,536,000 after purchasing an additional 265 shares in the last quarter. WFG Advisors LP boosted its position in Allergan PLC. by 20.9% during the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock worth $193,000 after purchasing an additional 137 shares in the last quarter. Finally, Toronto Dominion Bank boosted its position in Allergan PLC. by 25.2% during the second quarter. Toronto Dominion Bank now owns 113,770 shares of the company’s stock worth $27,651,000 after purchasing an additional 22,873 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.